63.26
price up icon1.43%   0.89
 
loading
Schlusskurs vom Vortag:
$62.37
Offen:
$62.22
24-Stunden-Volumen:
646.46K
Relative Volume:
0.58
Marktkapitalisierung:
$4.38B
Einnahmen:
$35.93M
Nettoeinkommen (Verlust:
$-244.56M
KGV:
-16.02
EPS:
-3.95
Netto-Cashflow:
$-157.31M
1W Leistung:
+15.04%
1M Leistung:
+19.12%
6M Leistung:
+55.70%
1J Leistung:
+13.41%
1-Tages-Spanne:
Value
$61.51
$63.45
1-Wochen-Bereich:
Value
$55.19
$64.00
52-Wochen-Spanne:
Value
$33.19
$64.00

Merus N V Stock (MRUS) Company Profile

Name
Firmenname
Merus N V
Name
Telefon
31 030 253 8800
Name
Adresse
YALELAAN 62, 3584 CM UTRECHT
Name
Mitarbeiter
260
Name
Twitter
@MerusNV
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
MRUS's Discussions on Twitter

Vergleichen Sie MRUS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MRUS
Merus N V
63.26 4.10B 35.93M -244.56M -157.31M -3.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Merus N V Stock (MRUS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-13 Eingeleitet Piper Sandler Overweight
2025-02-07 Eingeleitet Wells Fargo Overweight
2024-11-21 Eingeleitet Goldman Buy
2024-10-24 Eingeleitet UBS Buy
2024-03-28 Eingeleitet Truist Buy
2024-03-04 Bestätigt Needham Buy
2023-11-02 Eingeleitet Canaccord Genuity Buy
2023-08-21 Eingeleitet TD Cowen Outperform
2022-08-02 Eingeleitet Stifel Buy
2022-02-11 Eingeleitet BMO Capital Markets Outperform
2022-02-10 Eingeleitet Needham Buy
2021-11-17 Fortgesetzt Guggenheim Buy
2021-06-07 Hochstufung Citigroup Neutral → Buy
2021-04-08 Eingeleitet William Blair Outperform
2021-03-16 Eingeleitet SVB Leerink Outperform
2020-06-26 Eingeleitet H.C. Wainwright Buy
2020-05-27 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2019-11-20 Fortgesetzt Guggenheim Buy
2019-06-28 Eingeleitet ROTH Capital Buy
2019-04-12 Fortgesetzt Guggenheim Buy
2019-04-03 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2019-03-27 Eingeleitet Berenberg Buy
2018-01-02 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2017-09-15 Eingeleitet RBC Capital Mkts Outperform
2017-03-21 Herabstufung Citigroup Buy → Neutral
2016-12-22 Hochstufung Citigroup Neutral → Buy
2016-11-07 Herabstufung Citigroup Buy → Neutral
2016-06-13 Eingeleitet Citigroup Buy
2016-06-13 Eingeleitet Guggenheim Buy
2016-06-13 Eingeleitet Wedbush Outperform
Alle ansehen

Merus N V Aktie (MRUS) Neueste Nachrichten

pulisher
Jul 22, 2025

What analysts say about Merus N.V. stockHigh-impact investment strategies - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Merus N.V. Stock Analysis and ForecastPowerful market insights - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

What drives Merus N.V. stock pricePhenomenal trading returns - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

Is Merus N.V. a good long term investmentRapidly expanding wealth - Autocar Professional

Jul 20, 2025
pulisher
Jul 18, 2025

Merus Shares Soar 3.24% On Positive Cancer Study Update - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Merus NV stock hits all-time high, reaching 62.98 USD - Investing.com

Jul 18, 2025
pulisher
Jul 17, 2025

Merus Shares Surge Amid Promising Cancer Study - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Merus N.V. Advances in Head and Neck Cancer Treatment with Phase 3 Study - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

Learn to Evaluate (MRUS) using the Charts - news.stocktradersdaily.com

Jul 17, 2025
pulisher
Jul 17, 2025

Merus N.V. (NASDAQ:MRUS) Shares Sold by Teacher Retirement System of Texas - Defense World

Jul 17, 2025
pulisher
Jul 16, 2025

Merus N.V. (NASDAQ:MRUS) Given Average Rating of “Buy” by Analysts - Defense World

Jul 16, 2025
pulisher
Jul 16, 2025

Why Merus N.V. stock attracts strong analyst attentionFree Access to Community - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

How Merus N.V. stock performs during market volatilitySwing Trade Signals - newser.com

Jul 15, 2025
pulisher
Jul 15, 2025

Merus (MRUS) Gets a Buy from H.C. Wainwright - The Globe and Mail

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Merus N.V. stock price move sharplyAlpha Stock Ideas - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Insider Selling: Merus N.V. (NASDAQ:MRUS) COO Sells $924,275.00 in Stock - Defense World

Jul 14, 2025
pulisher
Jul 12, 2025

Merus (NASDAQ:MRUS) Upgraded by Wall Street Zen to Hold Rating - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success - sharewise.com

Jul 11, 2025
pulisher
Jul 09, 2025

Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III - Insider Monkey

Jul 09, 2025
pulisher
Jun 29, 2025

Merus N.V.: Making Progress (NASDAQ:MRUS) - Seeking Alpha

Jun 29, 2025
pulisher
Jun 26, 2025

Merus N.V.’s MCLA-129 Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jun 26, 2025
pulisher
Jun 23, 2025

Merus N.V.’s Promising Phase 3 Study in Head and Neck Cancer: What Investors Need to Know - TipRanks

Jun 23, 2025
pulisher
Jun 18, 2025

Merus gains after mid-stage trial data for lead asset in head and neck cancer - MSN

Jun 18, 2025
pulisher
Jun 15, 2025

(MRUS) Technical Data - news.stocktradersdaily.com

Jun 15, 2025
pulisher
Jun 14, 2025

Merus N.V.’s SWOT analysis: promising antibody platform drives stock potential - Investing.com India

Jun 14, 2025
pulisher
Jun 13, 2025

Merus N.V.’s SWOT analysis: promising antibody platform drives stock potential By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 11, 2025

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 10, 2025

The Netherlands: Merus raises US$300m from underwritten public offering - Investors in Healthcare

Jun 10, 2025
pulisher
Jun 08, 2025

Why Merus N.V. (MRUS) Crashed On Wednesday - MSN

Jun 08, 2025
pulisher
Jun 05, 2025

Merus N.V. announces proposed public offering of common shares - MSN

Jun 05, 2025
pulisher
Jun 05, 2025

Merus dips 7%, prices $300M stock at $57 per share - MSN

Jun 05, 2025
pulisher
Jun 05, 2025

Merus Announces Public Offering of Common Shares - TipRanks

Jun 05, 2025
pulisher
Jun 04, 2025

Merus Raises $300m After ASCO Success - insights.citeline.com

Jun 04, 2025
pulisher
Jun 04, 2025

Sector Update: Health Care Stocks Mixed Premarket Wednesday - marketscreener.com

Jun 04, 2025

Finanzdaten der Merus N V-Aktie (MRUS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):